Global Leukemia Therapeutics Market

Leukemia Therapeutics Market

Leukemia is a type of blood cancer caused by gene mutation leading to abnormal development of WBCs in the bone marrow and causes leukemia. Leukemia is also caused due to risk factors such as genetic disorders such as Down syndrome, previous cancer treatments, exposure to chemicals, smoking, and family history of leukemia or other blood disorders. The major types of leukemia are Acute Myeloid Leukemia (AML), Chronic Myelogenous Leukemia (CML), and Chronic Lymphocytic Leukemia (CLL), Acute Lymphocytic Leukemia (ALL). The majority of the AML, CML & CLL cases could be observed in adult populations, and ALL could be seen in all age groups. Leukemia treatment is based on its type, age, and ability to cope-up with the treatments. 

Market Size & Growth Rate: 

The leukemia therapeutics market was valued at USD 13.5 billion in 2021 and is projected to reach USD 17.1 billion by 2027, with a CAGR of 7.2% over the forecast period 2022-2027. The growth could be attributed to the return of demand to pre-pandemic levels, increasing authorization of novel & innovative medicines, extensive research, disease prevalence, and immunotherapies. 

Market Dynamics: 

On account of the growing number of people suffering from leukemia, the leukemia therapeutics treatment market has been driven by technological research & developments, the merging of healthcare organizations and new approvals in the field of blood cancer diagnostics across the globe. 

The Leukemia & Lymphoma Society Therapy Acceleration Program (LLS TAP)-April 2021, announced five new investments in increasing the development of new and improved immunotherapies in Abintus Bio, Nexlmmune, Caribou Biosciences and Immune-Onc Therapeutics for the treatment of leukemia cancer. 

Moreover, raising public awareness about the benefits of preventive healthcare is likely to move the demand for leukemia therapeutics treatment forward throughout the forecast period. Additionally, the Government initiatives and programs at increasing cancer awareness are expected to drive leukemia therapeutics treatment market expansion until 2027. 

Market Drivers: 

• The growing research and technological development activities. 

• Increasing product approval and product launch by the market players are expected to propel the leukemia therapeutics market, and also technological developments are likely to create various new opportunities that will impact this leukemia therapeutics market growth in the forecast period. For instance, 

• In May 2022, Ivosidenib (Tibsovo, Servier Pharmaceuticals LLC) received FDA approval for combination with azacitidine in newly diagnosed AML with a susceptible IDH1 mutation in adults 75 years and older. 

• On June 2021, Jazz Pharmaceuticals received FDA approval for a new form of Rylaze (asparaginase erwinia chrysanthemi recombinant rywn) to be developed as part of a treatment for children and adults with ALL 

• In October 2021, Kite Pharma received FDA approval for use of the CAR T-cell therapy brexucabtagene autoleucel developed by Tecartus (the first CAR T-cell therapy approved) in adults with B-cell precursor ALL 

• In November 2018, Pfizer Inc. received U.S. FDA approval for Glasdegib (DAURISMO), the Hedgehog pathway inhibitor for the treatment of adults suffering from AML 

• Increasing incidence of leukemia to boost leukemia therapeutics market growth. 

• One of the foremost driving factors influencing the global market is the increasing prevalence of leukemia across the globe, according to the National Cancer Institute (NCI), approximately 1.5% of people were diagnosed with leukemia during their lifetime. Additionally, in the report-2022, the estimated number of living people with new leukemia cases will be 60,650, and the number of death cases will be 24,000 in the United States. 

• According to the American Cancer Society-2022, the CLL segment is anticipated 20,160 diagnosis cases including both children & adults in US leukemia therapeutic market, as CLL is the first line of treatment for it followed by AML and CML. 

Get more details on this report - Request Free Sample

• Substantial progress has been made against cancer in recent decades. As of 2019, the rate has declined by 32%, mostly because of advances in early detection and treatment for some cancers including leukemia. It reflects largely driven by progress against leukemia cancer. 

Challenges: 

• The high cost of treatment and stringent regulatory scenario restrain the market growth. 

• High cost of treatment and stringent regulatory scenario restraint the market growth over the forecast period. For instance, the NCI-2022 report estimates that cancer-related direct medical costs in the US were USD 183 billion in 2015 and are projected to increase to USD 246 billion by 2030, a 34% increase based only on population growth and aging. 

• The low diagnosis rate of leukemia & lack of proper healthcare facilities in developing countries 

• Adverse reactions of leukemia therapeutics 

Competitive landscape:                                                                                                                     

Novartis International AG, Bristol Myers Squibb, Sanofi S.A, Pfizer Inc., Amgen Inc., Takeda Pharmaceutical, Celgene Corporation, GlaxoSmithKline plc, Abintus Bio, Nexlmmune, Exelixis Inc., MorphoSys AG, Otsuka Holdings Company Ltd, AbbVie, Ambit Biosciences corporation, Ariad Pharmaceuticals, Gennzme Corporation, Rpche,  and Others. 

Key Developments: 

Get more details on this report - Request Free Sample

Regional Analysis: 

North America was the largest region in the leukemia therapeutics market in recent years and it is anticipated to capture the highest share of this market over the forecast period 2022-2027, with the U.S. accounting for the maximum contribution and it has well-developed structural healthcare systems. In addition, the high prevalence of leukemia and the rising geriatric population, based on the NCI-2022 report, leukemia represents 3.2% of all new cancer cases in the U.S., and the incidence rate increased in children and adolescents by about 1% per year and was stable in adults ages 20 and older. The presence significant of key players, some of the best research universities, and encouraging new product developments & launches for research lead to more significant assets in the pipeline. For instance, 

• In October 2022, The American Cancer Society (ACS) approved funding for 89 new Extramural Discovery Science (EDS) research grants totaling USD 54.3 million. It will fund investigators at 65 institutions across the United States from January 1, 2023.?                                                                                                       

• In November 2021, Pfizer Company acquired Trillium Therapeutics for approximately USD 2.22 billion, to enhance its oncology portfolio with the addition of next-generation immune therapies. 

And a few more factors also reflect the growth of the market in this region like the large population, growing economy, and better access to insurance-policies availability of crowdfunding and support from various stakeholders fuels the USA the most attractive leukemia therapeutics market. 

Europe also remains a favorable region similar to the north american region. In recent times there is increased use of leukemia therapeutics due to the rising number of cancer diseases in these regions. The rising aging population, lifestyle factors, and increasing awareness of healthcare are some of the key driving factors for the growth of the global leukemia therapeutics market. However, the presence of highly skilled researchers, a developed R&D ecosystem, and support from government agencies and regulatory bodies are the major driving factors in Europe. 

Asia-Pacific is expected to be the fastest-growing region in the forecast period due to a favorable regulatory climate, increasing investments, and high unmet medical needs to drive market access in key markets such as Japan, China, Australia, Singapore, and India. Rising strategic partnerships and acquisitions by the market players are expected to bolster the market growth. For instance, 

• In April 2019, Astellas Pharma Inc.(Japan) and Concerto HealthAI, collaboratively launched a Real-World Evidence (RWE) initiative on acute myeloid leukemia to improve the treatment of patients suffering from FLT3 mutation-positive AML.   

• On September 2018, Blinatumomab received approval in Japan for the treatment of refractory B-cell ALL. 

Healthcare including the leukemia market in the Middle East is gaining significant progress on account of various factors including government initiatives to encourage medical tourism, evolving health insurance policies, and growing propensity among the local population to consume digital health services. The leukemia therapeutic market is primarily dominated by five countries such as Saudi Arabia, Iran, Israel, Egypt, and UAE. Moreover, all together cover more than 85% of the Middle East healthcare market. 

Latin America has contributed to the poor growth in the leukemia market, due to a lack of approved treatment options, insubstantial low infrastructure in healthcare platforms, along with a lack of awareness about the impacts of epilepsy on the quality of life of the affected, is hindering the prospects 

Pipeline:                                                                                                                                           

The major healthcare companies are working to advance the pipeline space and anticipated growth potential of the leukemia pipeline platform. Some of the key Leukemia market players proactively working to develop potential drug candidates to improve leukemia treatment options. 

• In September 2022, Oryzon Genomics conducted a study trial to assess the safety and efficacy of RP2D with Iadademstat + Gilteritinib in the FLT3-mutated recurrent AML condition 

• In October 2022, Novartis announced that to compare the efficacy of asciminib with bosutinib in the treatment of patients with CML-CP in phase 3 and having previously been treated with a minimum of two prior ATP-binding sites TKIs. 

• On October 2022, Hemavant Sciences GmbH conducted a Phase1 trial to evaluate the safety, pharmacokinetics, and pharmacodynamics of splicing modulator H3B-8800 (RVT-2001) for subjects with AML, and CML 

• In November 2021, Innovent Biologics and Ascentage announced that the novel drug olverembatinib has been approved by the China National Medical Products Administration (NMPA) for the treatment of adult patients with tyrosine kinase inhibitor (TKI)-resistant chronic-phase Chronic Myeloid Leukemia (CML-CP) as confirmed by a validated diagnostic test. 

• In December 2021, Sun Pharma announced an abstract on updated safety and efficacy of vodobatinib clinical data in CML by US FDA and EMA. Now, the phase 2 study has been initiated and is recruiting globally. 

Market Segments: 

• The global Leukemia therapeutics market estimates (Value USD Million) & Forecasts and Trend Analyses, 2022 to 2027 based on the Type of Leukemia 

• Chronic Myeloid Leukemia (CML) 

• Chronic Lymphocytic Leukemia (CLL) 

• Acute Lymphocytic Leukemia (ALL) 

• Acute Myeloid Leukemia (AML) 

• The global Leukemia therapeutics market estimates (Value USD Million) & Forecasts and Trend Analyses, 2022 to 2027 based on Treatment Type 

• Chemotherapy